March 22, 2017
Biosensors International Group, Ltd., announced the enrollment of the first American patient in LEADERS FREE II, its new BioFreedom Pivotal Study, conducted under an Investigational Device Exemption (IDE), which will include sites in the United States, Canada, Denmark, France Germany, Italy, and the United Kingdom.
1. This is the first step to USA entry for Biosensors
2. BioFreedom™ will be first stent that has 30 days ultra-short DAPT indication in the USA
3. BioFreedom™ will be one of the first non-USA stent to be approved in the US market
The press release had a total of 218 pickup for a total potential US audience of 88 million visitors per day.
As a reminder, the first European patient was enrolled in LEADERS FREE II on February 15th, 2017. See below access to the press release, which had a total of 62 pickup for a total potential EU audience of 1.9 million visitors per day: